Johnson & Johnson Romania’s pharma company Janssen will invest over EUR 1 million in research and development in Romania.
The company has expressed its willingness to collaborate with the local authorities to find new solutions to update the list of reimbursable drugs. Janssen is interested in continuing the investments in onco-hematology on the long term.
“We want to bring innovations for those conditions that affect small groups of patients and for which the need for treatment is still not covered at this time,” Janssen Romania general manager Christian Rodseth said.
Johnson & Johnson redirected almost 21% of its total turnover at group level to developing new molecules. The group launched 14 new drugs between 2009 and 2014. It plans to launch 10 new treatments and vaccines by 2019.